GSK and Enigma Diagnostics announce commercial partnership to develop point-of-care influenza diagnostics
Posted on July 22, 2009 at 03:51 AM EDT
GlaxoSmithKline (GSK) and Enigma Diagnostics Limited today announced that they have signed worldwide agreements to develop and supply the first point-of-care diagnostic influenza tests to identify specific influenza virus strains using its real-time Polymerase Chain Reaction (PCR) technology platform, the Enigma ML (Mini Laboratory).